MedTrace Logo

Preference Study With Elderly Patients Recurrent Ovarian Cancer

NCT00170690 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2013-06-03

No results posted yet for this study

Summary

Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)

Conditions

Interventions

DRUG

Treosulfan

Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc

DRUG

Treosulfan

Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc

Sponsors & Collaborators

  • North Eastern German Society of Gynaecological Oncology

    lead OTHER

Principal Investigators

  • Jalid Sehouli · Charite University, Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2011-12-31
Completion
2012-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170690 on ClinicalTrials.gov